Valion Bio (VBIO) Change in Receivables (2021 - 2025)
Valion Bio (VBIO) posted Change in Receivables of $6000.0 for Q3 2025, up 110.71% on a QoQ basis from -$56000.0 in Q1 2025, and up 185.71% year-over-year from $2100.0 in Q3 2024.
Powered by 
Analysis
Valion Bio (VBIO) Change in Receivables (2021 - 2025) Analysis & Trends
Valion Bio has reported Change in Receivables for 5 years, with the latest figure at $6000.0 in Q3 2025.
- On a quarterly basis, Change in Receivables rose 185.71% year-over-year to $6000.0 in Q3 2025; TTM through Sep 2025 was $5000.0, a 103.68% increase from a year earlier, with the FY2024 full-year figure at -$105000.0, down 256.72% from the prior year.
- Change in Receivables was $6000.0 for Q3 2025 at Valion Bio, up from -$56000.0 in the prior quarter.
- The five-year high for Change in Receivables was $118000.0 in Q3 2023, with the low at -$100000.0 in Q1 2024.
- Average Change in Receivables over 5 years is $250.0, with a median of -$2500.0 recorded in 2021.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables surged 700.0% in 2023, then slumped 222.58% in 2024.
- Over 5 years, Change in Receivables stood at -$2000.0 in 2021, then sank by 100.0% to -$4000.0 in 2022, then soared by 700.0% to $24000.0 in 2023, then jumped by 129.17% to $55000.0 in 2024, then plunged by 89.09% to $6000.0 in 2025.
- The last three Change in Receivables figures came in at $6000.0 (Q3 2025), -$56000.0 (Q1 2025), and $55000.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Valion Bio | 298,792.01 | -1.90 Mn | -45,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 6,000.00 |
| Mar 31, 2025 | -56,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Sep 30, 2023 | 118,000.00 |
| Jun 30, 2023 | -44,000.00 |
| Mar 31, 2023 | -31,000.00 |
| Dec 31, 2022 | -4,000.00 |
| Mar 31, 2022 | 30,000.00 |
| Dec 31, 2021 | -2,000.00 |
| Sep 30, 2021 | -3,000.00 |
| Jun 30, 2021 | 38,000.00 |
| Mar 31, 2021 | 33,000.00 |